(GILD) Gilead Sciences - Ratings and Ratios
Antivirals, Oncology, Hepatitis, Covid, Hiv
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 25.3% |
| Value at Risk 5%th | 39.1% |
| Relative Tail Risk | -6.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.39 |
| Alpha | 41.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.303 |
| Beta | 0.365 |
| Beta Downside | 0.377 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| Mean DD | 8.55% |
| Median DD | 7.58% |
Description: GILD Gilead Sciences September 25, 2025
Gilead Sciences (NASDAQ:GILD) is a U.S.–based biopharmaceutical firm that discovers, develops, and commercializes medicines targeting unmet medical needs across the United States, Europe, and other global markets. Its core therapeutic areas include HIV/AIDS (e.g., Biktarvy, Genvoya, Truvada), viral hepatitis (e.g., Epclusa, Harvoni), COVID-19 (Veklury), oncology (Yescarta, Tecartus, Trodelvy), pulmonary arterial hypertension (Letairis), and invasive fungal infections (AmBisome). The company also maintains an extensive network of collaborations with partners such as Merck, Galapagos, Janssen, and Arcus to broaden its pipeline.
In fiscal 2023 Gilead reported revenue of approximately $27.3 billion, driven primarily by its HIV franchise (+7% YoY) and a modest rebound in hepatitis sales, while Veklury contributed less than 2% of total revenue as COVID-19 demand waned. R&D expenditure was $5.8 billion (≈21% of revenue), reflecting heavy investment in next-generation oncology and cell-therapy assets. The balance sheet remained strong with $13 billion in cash and marketable securities, providing flexibility for potential acquisitions or accelerated development of late-stage candidates. These figures assume the company’s publicly filed 10-K data are accurate and do not account for any post-year-end adjustments.
Key drivers of Gilead’s outlook include: (1) the durability of its HIV product line amid growing competition from generic entrants and pricing pressure in major markets; (2) the success of its oncology pipeline-particularly the upcoming Phase III readout for Trodelvy in triple-negative breast cancer, which could unlock a multi-billion-dollar revenue stream; and (3) broader sector dynamics such as the biotech industry’s elevated cost-of-capital environment and the FDA’s evolving accelerated-approval pathways, which together shape the risk-adjusted return profile of new therapeutics.
For analysts looking to deepen their valuation framework, a quick review of Gilead’s metrics on ValueRay can help surface comparable peer multiples and scenario-based cash-flow models without committing to a full research report.
GILD Stock Overview
| Market Cap in USD | 155,333m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1992-01-22 |
| Return 12m vs S&P 500 | 29.3% |
| Analyst Rating | 4.13 of 5 |
GILD Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 3.10% |
| Yield on Cost 5y | 7.99% |
| Yield CAGR 5y | 3.16% |
| Payout Consistency | 100.0% |
| Payout Ratio | 38.3% |
GILD Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 18.46% |
| CAGR/Max DD Calmar Ratio | 0.69 |
| CAGR/Mean DD Pain Ratio | 2.16 |
| Current Volume | 10239.7k |
| Average Volume | 6881.9k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (8.11b TTM) > 0 and > 6% of Revenue (6% = 1.75b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA -1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.17% (prev 10.80%; Δ 8.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 9.67b > Net Income 8.11b (YES >=105%, WARN >=100%) |
| Net Debt (17.61b) to EBITDA (13.67b) ratio: 1.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.25b) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 78.71% (prev 76.11%; Δ 2.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.45% (prev 51.90%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.70 (EBITDA TTM 13.67b / Interest Expense TTM 1.02b) >= 6 (WARN >= 3) |
Altman Z'' 3.00
| (A) 0.10 = (Total Current Assets 17.87b - Total Current Liabilities 12.30b) / Total Assets 58.53b |
| (B) 0.22 = Retained Earnings (Balance) 12.82b / Total Assets 58.53b |
| (C) 0.19 = EBIT TTM 10.90b / Avg Total Assets 56.53b |
| (D) 0.35 = Book Value of Equity 12.86b / Total Liabilities 37.08b |
| Total Rating: 3.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.45
| 1. Piotroski 6.0pt |
| 2. FCF Yield 5.30% |
| 3. FCF Margin 31.50% |
| 4. Debt/Equity 1.16 |
| 5. Debt/Ebitda 1.29 |
| 6. ROIC - WACC (= 13.71)% |
| 7. RoE 40.70% |
| 8. Rev. Trend 43.92% |
| 9. EPS Trend 16.34% |
What is the price of GILD shares?
Over the past week, the price has changed by +1.30%, over one month by +2.06%, over three months by +9.80% and over the past year by +45.29%.
Is GILD a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GILD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 130.3 | 2.9% |
| Analysts Target Price | 130.3 | 2.9% |
| ValueRay Target Price | 157 | 24% |
GILD Fundamental Data Overview November 15, 2025
P/E Trailing = 19.3808
P/E Forward = 14.0449
P/S = 5.3403
P/B = 7.1077
P/EG = 0.2248
Beta = 0.334
Revenue TTM = 29.09b USD
EBIT TTM = 10.90b USD
EBITDA TTM = 13.67b USD
Long Term Debt = 22.14b USD (from longTermDebt, last quarter)
Short Term Debt = 2.81b USD (from shortTermDebt, last quarter)
Debt = 24.94b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.61b USD (from netDebt column, last quarter)
Enterprise Value = 172.93b USD (155.33b + Debt 24.94b - CCE 7.35b)
Interest Coverage Ratio = 10.70 (Ebit TTM 10.90b / Interest Expense TTM 1.02b)
FCF Yield = 5.30% (FCF TTM 9.16b / Enterprise Value 172.93b)
FCF Margin = 31.50% (FCF TTM 9.16b / Revenue TTM 29.09b)
Net Margin = 27.88% (Net Income TTM 8.11b / Revenue TTM 29.09b)
Gross Margin = 78.71% ((Revenue TTM 29.09b - Cost of Revenue TTM 6.19b) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 78.80%)
Tobins Q-Ratio = 2.95 (Enterprise Value 172.93b / Total Assets 58.53b)
Interest Expense / Debt = 1.03% (Interest Expense 256.0m / Debt 24.94b)
Taxrate = 16.18% (589.0m / 3.64b)
NOPAT = 9.14b (EBIT 10.90b * (1 - 16.18%))
Current Ratio = 1.45 (Total Current Assets 17.87b / Total Current Liabilities 12.30b)
Debt / Equity = 1.16 (Debt 24.94b / totalStockholderEquity, last quarter 21.54b)
Debt / EBITDA = 1.29 (Net Debt 17.61b / EBITDA 13.67b)
Debt / FCF = 1.92 (Net Debt 17.61b / FCF TTM 9.16b)
Total Stockholder Equity = 19.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.86% (Net Income 8.11b / Total Assets 58.53b)
RoE = 40.70% (Net Income TTM 8.11b / Total Stockholder Equity 19.93b)
RoCE = 25.93% (EBIT 10.90b / Capital Employed (Equity 19.93b + L.T.Debt 22.14b))
RoIC = 20.17% (NOPAT 9.14b / Invested Capital 45.31b)
WACC = 6.46% (E(155.33b)/V(180.27b) * Re(7.36%) + D(24.94b)/V(180.27b) * Rd(1.03%) * (1-Tc(0.16)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.08%
[DCF Debug] Terminal Value 77.65% ; FCFE base≈9.27b ; Y1≈8.89b ; Y5≈8.66b
Fair Price DCF = 124.5 (DCF Value 154.50b / Shares Outstanding 1.24b; 5y FCF grow -5.51% → 3.0% )
EPS Correlation: 16.34 | EPS CAGR: 15.30% | SUE: 1.63 | # QB: 1
Revenue Correlation: 43.92 | Revenue CAGR: 1.84% | SUE: 1.15 | # QB: 1
Additional Sources for GILD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle